#### Health**Equity**®

# Investor presentation

February 2022

#### Safe harbor

This presentation does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes. This presentation is a summary of information contained in our public filings filed with the Securities and Exchange Commission (SEC), which public filings are expressly incorporated herein by reference (see <a href="http://ir.healthequity.com/">http://ir.healthequity.com/</a>), and other publicly available information. Readers are encouraged to review our public filings for further information.

This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, statements regarding our industry, business strategy, plans, goals and expectations concerning our market position, product expansion, future operations, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Readers are encouraged to review our public filings with the SEC for further disclosure of other factors that could cause actual results to differ materially from those indicated in any forward-looking statements included herein.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

This presentation includes certain non-GAAP financial measures as defined by SEC rules. As required by Regulation G, we have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in our public filings.

No part of this presentation may be copied, recorded, or rebroadcast in any form.

# **Market Leader**

7.2M HSA Members
25% YoY growth


\$19.6B HSA Assets
37% YoY growth

120K Employer Clients
20% YoY growth


**185** Network Partners

~20K Integrations


# Sustainable market growth



## **Outgrowing the market**




#### Record HSA sales








### **Expanding ecosystem**





6 HealthEquity direct to consumer HSA opened in FY22



<sup>&</sup>lt;sup>1</sup> Aite Group survey of U.S. private sector employers, February 2019 – channels employers use for HSA administration

<sup>&</sup>lt;sup>2</sup> HealthEquity network partners as of January 2022

<sup>3</sup> Employers clients served estimated as of January 2022

<sup>4</sup> Current Health Equity defined contribution record keeper partners' total DC assets as reported by them as a percentage of the approximately \$8 trillion DC market - DOL, PPP Bulletin: Abstract of 2018 Form 5500 Annual Reports, September 2021 Proprietary research February 2019 - of the 175 brokers and advisors surveyed. WageWorks and Health Equity combined to be the most recognized benefit providers

# **Example | BlueFit integration**


HealthEquity is the integrated provider in the BlueFit product launched November 2021





- Employer contributes 30% of the deductible to an HSA
- +\$1,800 in HSA employer contribution per family and \$600 in rewards

## **Balance growth**





Account maturity

Average age

**3.9** Years

Balance Growth

Average growth

~2X
In five years

~4X
In ten years

### **Example | Integrated Open Enrollment**



- Year-round engagement
- Personalized learn sites
- Employer-sponsored virtual events

# **Acquired portfolios**

#### **HealthEquity HSA portfolio acquisitions**

Portfolio	Acquired	HSAs In thousands	Assets In millions
Fifth Third Bank	Q3 FY22	160	\$490
Further	Q4 FY22	580	\$1,900
HSA Administrators	Q1 FY23*	87	\$1,300
Total		827	\$3,690

37% YoY HSA asset growth

20%
YoY HSA asset growth excluding acquired portfolios

# Improving yields

#### Multi-year tailwinds

- Just ~10% of HSA cash in enhanced rate products at FYE22
- Improving rates on bank term deposits
- Fed rate hikes under policy normalization

Yield outlook			
	FY 2023	FY 2022 <sup>(1)</sup>	
HSA cash yield	1.55% at or above	~1.75%	

#### **Administrative CDBs**

#### Market-wide HSA and CDB growth



#### HealthEquity HSA and CDB growth




#### **FYE22** sales metrics results

Sales metrics (1)				
HealthEquity at January 31,				
	2022 (A)	YoY Growth	2021 (A)	
HSAs (millions)	7.2	25%	5.8	
HSA cash (\$billions)	\$12.9	28%	\$10.1	
HSA investments (\$billions)	\$6.7	58%	\$4.2	
Total HSA assets (\$billions)	\$19.6	37%	\$14.3	
Total accounts (millions)	14.4	12%	12.8	
Employer clients	120,000	20%	~100,000	
Network partners	185	6%	174	

# **FYE 22 capital structure outlook**


(\$ in millions)	January 31, 2022(E)	October 31, 2021	January 31, 2021
Cash, cash equivalents & marketable securities	~\$225	\$649 <sup>1</sup>	\$329
Long-term debt, net of debt issuance costs (\$1B available LOC)	~\$930	\$930	\$987
Debt to EBITDA leverage	~3x	~2.5x	~3x

#### **HSA** key metrics







25% total / 12% organic growth YoY



- \$5.3B net increase YoY
- 37% total / 20% organic growth YoY

#### Fiscal third quarter financial results





- 0% growth in Q3 revenue YoY
  - 2% Q3 decrease in Service Revenue
  - 1% Q3 growth in Custodial Revenue
  - 8% Q3 growth in Interchange Revenue

- 0% Adjusted EBITDA growth Q3 YoY
- 57% Q3 Gross margin
- 34% Q3 Adjusted EBITDA margin

### Foundation of promises kept

**42%**5-yr revenue CAGR <sup>1</sup>

Growth

30 Consecutive QUARTERS

Beating adjusted EBITDA consensus <sup>2</sup>

**Visibility** 

43%

5-yr Adjusted EBITDA CAGR <sup>1</sup>

**Profitable** 

+10<sub>yrs</sub>

Increased market share <sup>3</sup>

Sustainable

<sup>1-</sup> HealthEquity data based on changes from fiscal years 2016 to 2021

<sup>2-</sup> Based on FactSet consensus during quarterly reporting between fiscal years 2014 to 2022

<sup>3-</sup> Based on Devenir Research HSA reports December 2010 to December 2021

#### **Guidance**

Business outlook				
HealthEquity fiscal year ending January 31, 2022				
Guidance as of: (\$ in millions, except per share)	February 22, 2022*	December 6, 2021		
Revenue	\$754 - \$756	\$750 - \$755		
Non-GAAP net income**	\$108 - \$110	\$108 - \$112		
Non-GAAP Net income per diluted share**	\$1.30 - \$133	\$1.30 - \$135		
Adjusted EBITDA**	\$232 - \$235	\$230 - \$235		

# Health**Equity**®